Why ImmunoGen (IMGN) Shares Are Surging Today

ImmunoGen Inc (NASDAQ:IMGN) shares are surging Friday morning following its impressive first-quarter performance.
IMGN reported Q1 revenues of $49.9 million, easily surpassing the consensus of $20.47 million and higher than $38.1 million a year ago.
The increase was primarily driven by Elahere net sales and recognition of a $15 million upfront fee received under a multi-target license and option agreement executed in the first quarter with Vertex Pharmaceuticals Inc (NASDAQ:VRTX).
It was partially offset by $30.8 million of license fees recorded as revenue in the prior year under its collaboration and license agreements with Huadong Medicine and Eli Lilly And Co (NYSE:LLY).
The revenues included $29.5 million of net product revenues from Elahere (mirvetuximab soravtansine-gynx) for the first full quarter of launch following approval in November 2022 for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The company reported a net loss of $(41.0) million, or $(0.16) per share, compared to a loss of $(24.1) million, or $(0.10) per share a year ago.
Guidance: ImmunoGen expects FY23 sales, excluding Elahere, of $45-$50 million, up from prior guidance of $30-$35 million.
ImmunoGen expects that its current cash, including the $75 million received under the term loan facility, combined with anticipated product and collaboration revenues, will fund operations into 2025.
Additionally, the company increased its operating expense guidance to $320-$335 million ($310-$320 million expected previously), reflecting greater spending supporting Elahere's launch and expected growth trajectory.
Price Action: IMGN shares are up 21.76% at $5.26 on the last check Friday.

LLYEli Lilly and Co

$1182.00-0.55%

Overview

VRTXVertex Pharmaceuticals Inc

$486.110.15%

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Benzinga

Benzinga

ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug